MEMORANDUM (DMS-15)

To: Pharmacists and Prescribers

From: Division of Medical Services (DMS)

Date: March 26, 2020

Re: Addition of Certain Inhalers to the Preferred Drug List (PDL)

Amended on May 19, 2020

This guidance ends at the expiration of the public health emergency as declared by the Governor of Arkansas.

In response to the COVID-19 outbreak in Arkansas and the state and nationwide shortages of rescue Albuterol and Levalbuterol HFA inhalers, DMS has temporarily changed the status of all brand and generic rescue HFA inhalers to add them to the preferred drug list (PDL). This change is implemented effective March 21, 2020 and will be effective for the next thirty (30) days, with the option of extending for additional thirty-day periods, as needed.

To ensure quality and consistency of care to Medicaid beneficiaries, DMS will coordinate with the Office of the Medicaid Inspector General (OMIG) to conduct retrospective reviews and audits inhalers dispensed during this time. Please keep all records of services as required by Medicaid billing rules.